May 13, 2021
Christopher Rohde, Ph.D. to Join Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.
May 13, 2021 07:30 AM Eastern Daylight Time
BROOKLYN, N.Y.–(BUSINESS WIRE)–Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced the appointment of Christopher Rohde, Ph.D. to the Company’s Scientific Advisory Board, effective May 13, 2021.
Dr. Rohde is Co-Founder and Chief Technology Officer at Factor Bioscience. Dr. Rohde is also Co-Founder and President of Novellus Therapeutics. Brooklyn ImmunoTherapeutics acquired an exclusive license for the mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited. Dr. Rohde is currently leading Factor’s efforts to apply their RiboSlice™ gene-editing technology, and FactorStem™ cell-reprogramming and differentiation technologies to the development of new research models, including high-throughput screening-compatible human cell libraries. His work is described in numerous peer-reviewed publications and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many other publications. Chris Rohde earned his Ph.D. from the Massachusetts Institute of Technology (MIT) in 2011.
“As Co-founder and Chief Technology Officer at Factor Bioscience, Dr. Rohde brings a unique and unparalleled understanding of the gene editing and cell therapy technology which Brooklyn has in-licensed to our Scientific Advisory Board,” said Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President of Brooklyn. “His in-depth knowledge and perspective will allow us to target disease at the molecular level. This is a very exciting time at Brooklyn and we are looking forward to working with Chris to rapidly advance our potential treatments for oncology, blood disorders, and monogenic diseases.”
“Brooklyn ImmunoTherapeutics is well-positioned to become a leader in gene editing and cell reprograming using Factor’s RiboSlice™ gene-editing technology, and FactorStem™ cell-reprogramming and differentiation technologies,” said Dr. Rohde. “I look forward to working with colleagues on the Scientific Advisory Board to optimize this leading-edge technology to develop new therapies for patients living with cancer and blood disorders.”
February 28, 2023
Factor Bioscience Announces Publication of Preclinical Results of Aerosolized mRNA For the Treatment of Pneumonia
February 22, 2023
Eterna Therapeutics Enters Into Option and License Agreement With Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
January 4, 2023
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
May 16, 2022
Factor Bioscience to Deliver Four Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting